Director, Market Access - Strategic Pricing
Ferring Pharmaceuticals
Summary
As a strategic leader within the Market Access team, you will set the pricing direction for our full Ferring portfolio across both Medical (Part B / Buy-and-Bill) and Pharmacy (Part D / Commercial) benefits. This position will shape pricing strategy for in-line products and business development opportunities, oversee the ASP scorecard, and guide decision-making at the US Pricing Committee.
Job description
Responsibilities
Pricing Strategy Development (In-line & Business Development)
- Set the integrated pricing strategy for specialty products across Medical Benefit (Buy-and-Bill/ASP) and Pharmacy Benefit (Rebate/PBM) structures.
- Shape pricing and reimbursement strategy to inform the evaluation of business development and L&A opportunities.
- Define the approach to value-based or innovative contracting models and their role in specialty brand strategy.
Pricing Committee Leadership & Direction
- Frame list price, discounting, and net price recommendations for committee decision, setting direction on key strategic trade-offs.
- Synthesize market trends, competitive dynamics, and the payer landscape into strategic recommendations for senior leadership.
ASP Scorecard Oversight
- Oversee the ASP scorecard to monitor channel pricing performance and inform pricing strategy.
Gross-to-Net (GTN) Strategy & Ad-Hoc Pricing Guidance
- Direct ad-hoc pricing and GTN reviews to identify margin leakage and assess the commercial viability of proposed contracts.
- Guide the organization's understanding of how discounts, rebates, and fees shape realized net price across channels, and use it to inform contracting strategy.
- Provide strategic oversight of select GTN forecasting, partnering with Finance to align GTN assumptions with commercial forecasts.
Consultation & Business Partnering
- Act as a trusted strategic advisor to select Business Units, translating pricing and GTN insights into practical guidance.
Strategy & Tactics
- Translate pricing strategy into executable tactics aligned with Global and local price guidance and the approval process.
- Assess the long-term impact of Government or Industry changes on pricing, GTN, and portfolio performance, and recommend response strategies.
Internal & External Price Forecasting & Management
- Set direction for internal and external price management to support planning, contracting, and committee decisions.
Requirements
- Minimum of 10 years in pharmaceutical pricing, market access, or commercial strategy, with a specific focus on specialty medications and a track record of strategic leadership
- Proven expertise in shaping strategy for products across both Medical (J-code/ASP) and Pharmacy (NDC/PBM) benefit channels
- Ability to translate complex pricing and net price dynamics into clear strategic choices and recommendations
- Proven ability to influence senior stakeholders across Commercial, Finance, and Market Access in a matrix environment
- Exceptional ability to present strategic recommendations to the US Pricing Committee and senior executives
- Bachelor's degree in Finance, Economics, or Life Sciences
- MBA preferred
Benefits
- Comprehensive Healthcare
- 401(k) Matching
- Short & Long-Term Disability
- Basic Life Insurance
- Wellness Benefits
- Tuition Reimbursement
- Paid Parental Leave
- Paid Holidays
- Vacation Time
- Sick Time
- Annual Bonus
Company overview
Ferring Pharmaceuticals is a Swiss multinational biopharmaceutical company specializing in reproductive health, maternal health, gastroenterology, and urology. Founded in 1950 by Dr. Frederik Paulsen Sr. and Dr. Eva Paulsen in Malmö, Sweden, the company has grown into a global leader with headquarters in Saint-Prex, Switzerland. Ferring employs over 7,000 people worldwide and operates in more than 50 countries, marketing its products in over 100 countries. The company is privately owned and research-driven, with a strong commitment to building families and helping people live better lives. Ferring has been developing treatments for mothers and babies for over 50 years and is at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. The company's portfolio includes leading products such as Menopur for reproductive medicine, Pentasa for gastroenterology, and Adstiladrin for bladder cancer treatment. With manufacturing facilities across Europe, South America, China, India, and the United States, Ferring maintains a robust global presence while maintaining its focus on specialty biopharmaceuticals that address significant unmet medical needs.